Australian Operations
Include All CSL Sites


Safinamide (as mesilate) tablet

XADAGO is indicated for the treatment of fluctuating idiopathic Parkinson’s disease, as add-on therapy to a regimen that includes levodopa.

This product is available only with a doctor’s prescription.

Who is this information for?
This information is relevant in Australia and is intended for people who have been prescribed this product or health care professionals.

Consumer Medicine Information
The Consumer Medicine Information (CMI) is a leaflet written for consumers. The CMI contains information about the medicine including:
  • What this product is used for
  • How it works
  • How this product is given
  • Side effects
Xadago Consumer Medicine Information (PDF, 438KB)

Product Information
Product Information contains information to ensure the safe and effective use of a medicine. This document is approved by the Therapeutic Goods Administration and made available by Seqirus for you if you are a:
  1. qualified healthcare professional; or
  2. consumer, provided you have read the Consumer Medicine Information for the product; want further information on the product; and agree to consult with your healthcare professional if you have any questions in relation to the Product Information.
Xadago Product Information (PDF, 438KB)

Xadago is a trademark of Zambon S.p.A. Under Licence from Newron Pharmaceuticals S.p.A.
Xadago is distributed by Seqirus (Australia) Pty Ltd under license from Zambon S.p.A.

Last Updated: 23-11-2018
LinkedIn Twitter Facebook Google+
© 2019 Seqirus